EA202192138A1 - Гетероциклическое соединение и его применение - Google Patents

Гетероциклическое соединение и его применение

Info

Publication number
EA202192138A1
EA202192138A1 EA202192138A EA202192138A EA202192138A1 EA 202192138 A1 EA202192138 A1 EA 202192138A1 EA 202192138 A EA202192138 A EA 202192138A EA 202192138 A EA202192138 A EA 202192138A EA 202192138 A1 EA202192138 A1 EA 202192138A1
Authority
EA
Eurasian Patent Office
Prior art keywords
heterocyclic compound
applications
type
orexin
receptor
Prior art date
Application number
EA202192138A
Other languages
English (en)
Inventor
Ясуси Хаттори
Юхэи Миянохана
Юити Кадзита
Тацуки Койке
Ясутака Хоаси
Норихито Токунага
Александер Мартин Павличек
Цунео Ода
Тохру Миядзаки
Еситеру Ито
Кохеи Такеути
Кейсуке Имамура
Такахиро Сугимото
Original Assignee
Такеда Фармасьютикал Компани Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Такеда Фармасьютикал Компани Лимитед filed Critical Такеда Фармасьютикал Компани Лимитед
Publication of EA202192138A1 publication Critical patent/EA202192138A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Изобретение представляет гетероциклическое соединение, обладающее агонистическим действием к рецептору орексина 2 типа. Соединение, представленное формулой (I)где каждый символ такой, как описан в спецификации, или его соль, которое обладает агонистическим действием к рецептору орексина 2 типа и применимо в качестве агента для профилактики или лечения нарколепсии.
EA202192138A 2019-01-31 2020-01-30 Гетероциклическое соединение и его применение EA202192138A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019015488 2019-01-31
PCT/JP2020/004444 WO2020158958A1 (en) 2019-01-31 2020-01-30 Heterocyclic compound and use thereof

Publications (1)

Publication Number Publication Date
EA202192138A1 true EA202192138A1 (ru) 2022-03-10

Family

ID=69770989

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202192138A EA202192138A1 (ru) 2019-01-31 2020-01-30 Гетероциклическое соединение и его применение

Country Status (20)

Country Link
US (3) US11028048B2 (ru)
EP (1) EP3917616A1 (ru)
JP (2) JP7253640B2 (ru)
KR (1) KR20210121080A (ru)
CN (1) CN113395993B (ru)
AR (1) AR117916A1 (ru)
AU (1) AU2020215380A1 (ru)
BR (1) BR112021014180A2 (ru)
CA (1) CA3124536A1 (ru)
CL (1) CL2021001973A1 (ru)
CO (1) CO2021011188A2 (ru)
EA (1) EA202192138A1 (ru)
EC (1) ECSP21056325A (ru)
IL (1) IL284073A (ru)
MX (1) MX2021008241A (ru)
PE (1) PE20211700A1 (ru)
SG (1) SG11202106791XA (ru)
TW (1) TWI832962B (ru)
WO (1) WO2020158958A1 (ru)
ZA (1) ZA202106304B (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3155885A1 (en) 2019-11-25 2021-06-03 Lewis D. Pennington Substituted macrocyclic compounds and related methods of treatment
EP4066893A4 (en) 2019-11-27 2023-12-20 Takeda Pharmaceutical Company Limited HETEROCYCLIC COMPOUND
BR112023002957A2 (pt) 2020-08-18 2023-04-04 Merck Sharp & Dohme Llc Composto, composição farmacêutica, e, métodos para tratar narcolepsia e para tratar hipersonia em um sujeito mamífero
TW202227397A (zh) * 2020-09-03 2022-07-16 英商歐瑞夏治療公司 雙環的－雜環衍生物及相關用途
JP2023540350A (ja) * 2020-09-03 2023-09-22 センテッサ ファーマシューティカルズ （オレキシア） リミテッド 中環状または大環状ベンジル置換複素環誘導体およびオレキシン－２受容体アゴニストとしてのそれらの使用
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
WO2022207935A1 (en) * 2021-04-02 2022-10-06 Orexia Therapeutics Limited 2-(3-ethynylbenzyl)-substituted heterocycle derivatives as orexin-2 agonists
BR112023020104A2 (pt) 2021-04-02 2023-11-14 Takeda Pharmaceuticals Co Métodos para recuperação pós-operação, para facilitar a recuperação ou reduzir o tempo de recuperação da anestesia, para prevenir ou tratar distúrbios/depressão respiratória pós-operatória ou distúrbios/depressão respiratória induzida por opioides, sedação pós-operatória ou sedação induzida por opioides e para reduzir um efeito colateral de opioides
WO2023167925A1 (en) 2022-03-01 2023-09-07 Orexia Therapeutics Limited Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and related uses
WO2023199091A1 (en) 2022-04-12 2023-10-19 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2024095133A1 (en) 2022-10-31 2024-05-10 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2024095158A1 (en) 2022-10-31 2024-05-10 Takeda Pharmaceutical Company Limited Dosing of orexin type 2 receptor agonists

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6166193A (en) 1997-07-25 2000-12-26 Board Of Regents, University Of Texas System Polynucleotides encoding MY1 receptor
US6545127B1 (en) 1999-06-28 2003-04-08 Oklahoma Medical Research Foundation Catalytically active recombinant memapsin and methods of use thereof
EP1252329A4 (en) 1999-07-30 2004-12-22 Univ Leland Stanford Junior HYPOCRETINE AND HYPOCRETINE RECEPTORS FOR THE REGULATION OF SLEEP AND SLEEP DISORDERS
US6204245B1 (en) 1999-09-17 2001-03-20 The Regents Of The University Of California Treatment of narcolepsy with immunosuppressants
US7112566B1 (en) 1999-09-17 2006-09-26 The Regents Of The University Of California Systemic administration of Hypocretin-1
WO2001074162A1 (en) 2000-04-04 2001-10-11 The Regents Of The University Of California Treatment of sleep disorders with hypocretin-1
US20080260744A1 (en) 2002-09-09 2008-10-23 Omeros Corporation G protein coupled receptors and uses thereof
JP2006513702A (ja) 2002-09-09 2006-04-27 ヌラ インコーポレーティッド Ｇタンパク質共役受容体およびその使用
DK1572133T3 (da) 2002-12-13 2008-07-14 Janssen Pharmaceutica Nv Fremgangsmåde til identificering af modulatorer af den humane orexin-2-receptor
HUP0304101A3 (en) * 2003-12-22 2008-10-28 Sanofi Aventis Pyrazole derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates
JP5232987B2 (ja) 2006-04-14 2013-07-10 アボット ゲーエムベーハー ウント カンパニー カーゲー ドーパミンｄ３受容体の調節に応答する障害の治療に好適なアリールオキシエチルアミン化合物
AU2012200270A1 (en) * 2007-05-23 2012-02-09 Merck Sharp & Dohme Corp. Pyridyl piperidine orexin receptor antagonists
WO2009049215A1 (en) 2007-10-10 2009-04-16 Wake Forest University Health Sciences Methods to reduce the effects of sleep deprivation
US8258163B2 (en) 2008-06-04 2012-09-04 Board Of Regents, The University Of Texas System Small-molecule agonists for type-2 orexin receptor
WO2012137982A2 (en) 2011-04-05 2012-10-11 Takeda Pharmaceutical Company Limited Sulfonamide derivative and use thereof
TW201341380A (zh) * 2012-04-05 2013-10-16 Takeda Pharmaceutical 磺醯胺衍生物及其用途
SG11201502493XA (en) 2012-10-10 2015-04-29 Actelion Pharmaceuticals Ltd Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone derivatives
WO2014170343A1 (en) 2013-04-15 2014-10-23 Icm (Institut Du Cerveau Et De La Moelle Épinière) Depolarizing agents and nicotinic acetylcholine receptor modulators for treating dopaminergic-related disorders
WO2014198880A1 (en) 2013-06-14 2014-12-18 Ferrer Internacional, S.A. 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity
US20160250224A1 (en) 2013-09-24 2016-09-01 The Board Of Regents Of The University Of Texas System Orexin-control of bone formation and loss
US10172916B2 (en) 2013-11-15 2019-01-08 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating heart failure with agonists of hypocretin receptor 2
US9815787B2 (en) 2013-12-12 2017-11-14 University Of Tsukuba Sulfonamide derivative or pharmaceutically acceptable acid addition salt thereof
JP6552117B2 (ja) 2014-03-28 2019-07-31 国立大学法人 筑波大学 敗血症の予防治療剤
JP6663909B2 (ja) 2014-08-13 2020-03-13 エオラス セラピューティクス， インコーポレイテッド オレキシンレセプターモジュレーターとしてのジフルオロピロリジン
EP3029024A1 (en) 2014-12-02 2016-06-08 Ferrer Internacional, S.A. 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity
WO2016133160A1 (ja) 2015-02-19 2016-08-25 国立大学法人筑波大学 スルホンアミド誘導体またはその薬学的に許容される酸付加塩
JP6775803B2 (ja) 2015-06-12 2020-10-28 国立大学法人 筑波大学 スルホンアミド誘導体またはその薬学的に許容される酸付加塩
WO2017044889A1 (en) 2015-09-10 2017-03-16 The Regents Of The University Of California Lrh-1 modulators
ES2907373T3 (es) 2016-02-04 2022-04-25 Takeda Pharmaceuticals Co Compuesto de piperidina sustituida y uso de la misma
WO2018164191A1 (ja) * 2017-03-08 2018-09-13 武田薬品工業株式会社 置換ピロリジン化合物およびその用途
JP7012703B2 (ja) 2017-03-08 2022-02-14 武田薬品工業株式会社 置換ピロリジン化合物およびその用途
JP6574918B1 (ja) 2017-08-03 2019-09-11 武田薬品工業株式会社 複素環化合物およびその用途
WO2019027003A1 (ja) 2017-08-03 2019-02-07 武田薬品工業株式会社 複素環化合物およびその用途
WO2019112007A1 (ja) 2017-12-07 2019-06-13 国立大学法人 筑波大学 鎮痛薬による眠気の予防または治療薬
WO2020004536A1 (ja) 2018-06-29 2020-01-02 武田薬品工業株式会社 複素環化合物およびその用途
EP3816153B1 (en) 2018-06-29 2023-10-18 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US20220017514A1 (en) 2018-12-12 2022-01-20 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP3895707B1 (en) 2018-12-12 2023-10-04 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2020167701A1 (en) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. Pyrrolidine orexin receptor agonists
WO2020167706A1 (en) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists

Also Published As

Publication number Publication date
AR117916A1 (es) 2021-09-01
JP2023078426A (ja) 2023-06-06
AU2020215380A1 (en) 2021-08-19
AU2020215380A2 (en) 2021-08-19
CL2021001973A1 (es) 2022-04-08
US20200247747A1 (en) 2020-08-06
CN113395993A (zh) 2021-09-14
MX2021008241A (es) 2021-08-16
JP2022519331A (ja) 2022-03-22
US11028048B2 (en) 2021-06-08
CA3124536A1 (en) 2020-08-06
US20230040770A1 (en) 2023-02-09
ECSP21056325A (es) 2021-09-30
BR112021014180A2 (pt) 2021-09-21
KR20210121080A (ko) 2021-10-07
WO2020158958A1 (en) 2020-08-06
JP7253640B2 (ja) 2023-04-06
ZA202106304B (en) 2023-06-28
US20210276949A1 (en) 2021-09-09
SG11202106791XA (en) 2021-07-29
EP3917616A1 (en) 2021-12-08
TW202043196A (zh) 2020-12-01
CO2021011188A2 (es) 2021-10-29
CN113395993B (zh) 2024-02-20
IL284073A (en) 2021-08-31
PE20211700A1 (es) 2021-09-01
TWI832962B (zh) 2024-02-21

Similar Documents

Publication Publication Date Title
EA202192138A1 (ru) Гетероциклическое соединение и его применение
MY202221A (en) Heterocyclic compound and use thereof
EA201891742A1 (ru) Замещенное пиперидиновое соединение и его применение
EA202091893A1 (ru) Новые кристаллические формы
MX2021014441A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
MX2021014443A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
PH12019502118A1 (en) Heterocyclic compounds useful as dual atx/ca inhibitors
PH12019502252A1 (en) Gip receptor activating peptide
CU24572B1 (es) Compuestos derivados de 1,2,4-triazolonas 2,4,5-trisustituidas
EA201890913A1 (ru) Пиразоловые соединения в качестве ингибиторов акк и их применение
EA202092248A1 (ru) Замещенные соединения 4-аминоизоиндолин-1,3-диона, их композиции и способы лечения ими
MX2018006287A (es) Inhibidores de acc de triazol y usos de los mismos.
EA201890858A1 (ru) 2,4-дигидроксиникотинамиды как агонисты apj
MX2019014104A (es) Compuesto novedoso de bifenilo o sal del mismo.
EA202092716A1 (ru) Производные 2-(фенилокси- или фенилтио)пиримидина в качестве гербицидов
PH12019500039A1 (en) Heterocyclic compound and harmful arthropod controlling agent containing same
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων
EA202190464A1 (ru) Замещенные бензимидазолы в качестве ингибиторов pad4
EA201890208A1 (ru) Гербицидно-активные производные n-(1,3,4-оксадиазол-2-ил)арилкарбоксамида
MX2019014406A (es) Compuesto heterociclico y composicion que contiene el mismo.
EA202190070A1 (ru) Бициклические ингибиторы гистондеацетилазы
EA201990952A1 (ru) ПИРИДОНОВОЕ СОЕДИНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРА c-Met
EA202190298A1 (ru) Циклические динуклеотиды в качестве агонистов sting
CO2018007668A2 (es) Composición para el control de plagas y método para el control de plagas
MY192039A (en) N-(4-pyridyl)nicotinamide compound or salt thereof